Urgent.News

What's breaking now, across thousands of outlets.

More in Business

Innovent displays Phase I trial results for bispecific ADC IBI3001

Biopharmaceutical manufacturer Innovent Biologics showcased Phase I trial results at ESMO 2026 for IBI3001 a bispecific antibody drug conjugate targeting solid tumours

  • Innovent Biologics presents Phase 1 trial results for bispecific ADC IBI3001 at ESMO Congress.
  • 57 patients from China, Australia, and US participated in multinational study.
  • IBI3001 showed favorable safety and 30.2% overall objective response rate in advanced solid tumors.

More from Monday 26 October →